Value Of Dynamic Monitoring Of IL-17 Levels In Patients With CHB For Evaluation Of Antiviral Efficacy

Objective:To investigate the value of dynamic monitoring of IL-17 levels in patients with CHB by observing the changes of IL-17 levels in the course of antiviral therapy.Method:58 cases of hepatitis B patients treated with nucleoside analogues for 2 years or more than 2 years were selected as the study subjects, Another randomly selected 32 healthy people without liver disease as the control group.Baseline IL-17 levels in healthy people and the IL-17 levels at baseline,3, 6,12 months in CHB group were detected. At the same time, the value of ALT, HBeAg, HBeAb and HBV-DNA at the same time is also detected.ResuIts:(1)Compared with the healthy group, the level of IL-17 in CHB group was significantly higher(P<0.001). There was no significant difference in IL-17 levels between initial/treated treatment, gender, and age groups(P>0.05).(2)The levels of IL-17 at baseline,3,6,12 months were (101.49+27.27, 94.49+20.25,97.48+26.17,93.78+22.61) pg/ml, and the levels of IL-17 at 3,12 months compared with baseline were decreased (P<0.05); while The levels of ALT at baseline,3,6,12 months were (145.45+120.70,54.32+40.84,29.45 +11.47,27+15.58) IU/L;The levels of ALT at 3,6,12 months compared with baseline were decreased(P<0.05); The 4 time points of the HBV-DNA negative rates were 0,79.3%,94.8%,96.6%;The serological conversion rates of HBeAg were 0,15.5%,22.4%,37.9%, respectively.(3) Four time points of IL-17 levels and the same time point of HBeAg, HBeAb, ALT, HBV-DNA(lg) correlation analysis showed that the 6 months of IL-17 level related to HBeAg (R=0.324, P=0.013), HBeAb (R=-0.298, P=0.023), ALT (R=0.286, P=0.029). Twelfth months of IL-17 level related to HBeAg (R=0.401, P=0.002), HBeAb (R=-0.359, P=0.006). The rest were uncorrelated.(4) There was no significant difference in the overall IL-17 dynamic curve between different drug regimens(P>0.05).(5)Group on whether there was a virological response in 3 months, and the levels of IL-17 were different between the two groups (P=0.031), the group of virological response was lower, and there was no significant difference in ALT. According to whether there is serum conversion in HBeAg in 2 years to group, the differences of IL-17 (P<0.01) had significance,while ALT did not have, and the group of serum conversion was lower.^Conclusion:(1) IL-17 as a liver inflammation index, better than ALT, can be used for the dynamic monitoring of antiviral treatment process to assess the efficacy;(2) CHB patients treated with nucleoside analogues for 1 years, the inflammation of the liver has not yet completely subsided and patients with slow virological response and slow HBeAg serological conversion suggest that the inflammation subsided more slowly and need to be treated with liver protective drugs.